Pharmacy News

Image description

PTCB added as FIP observer organization

With its new status, PTCB will be able to participate in FIP working groups, nominations calls and other efforts while being included in the company’s dialogues and communications. 

Image description

The New York Times slams Valeant for major price hikes

The New York Times outlines the impact price increases of Valeant Pharmaceutical's Cuprimine has on one family, juxtaposing Valeant's pharmaceutical business model against the threat of government action. “Cuprimine is just one of many Valeant drugs whose prices have spiked as part of the company’s concerted strategy, which has richly rewarded its investors and made it one of Wall Street’s most popular health stocks,” the article said. “But Valeant’s habit of buying up existing drugs and raising prices aggressively, rather than trying to develop new drugs, has also drawn the ire of lawmakers and helped stoke public outrage against the growing trend of higher and higher drug prices imposed by big drug companies.” (New York Times)